CVMC Technology Methicillin Resistant Staphylococcus aureus (MRSA) bacteria are those that are resistant to beta lactam

antibiotics. These multidrug resistant bacteria are resistant to penicillins, cephem and aminoglycoside antibiotics individually. Vancomycin is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria.Although it has been used in the treatment of MRSA , vancomycin resistant Staphylococcus aureus have emerged, prompting the addition of a second antibiotic to the treatment regimen. Ceftriaxone is a third-generation cephalosporin antibiotic and it has broad spectrum activity against Gram-positive and Gram-negative bacteria Vancoplus:Vancomycin +Ceftriaxone Combination of Vancomycin and Ceftriaxone provides broad spectrum coverage and is shown to be more effective in antibacterial potency than monotherapy with the individual drugs alone. The FME (Fractional Maximal Effect.) value for the drug combination is 1.35.Any value above 1 reveals synergism. Vancoplus works at a lower MIC than either of the two drugs. Tissue penetration as well as penetration to BBB is higher. Chemical Incompatibilty: The incompatibility between the two drugs can be attributed to the possible precipitation reactions which may occur while coadministration, prompting separate administration of each drug. Physical incompatibility has already been described between vancomycin and ceftazidime (which belongs to the same class of drugs as ceftriaxone).These two drugs have been known to form yellow-white precipitates when co-administered. Based on the structural similarity between ceftazidime and ceftriaxone, it can be deduced that the incompatibility between ceftriaxone and vancomycin is due to precipitation reactions between the two. Also, the two drugs vary amongst each other in terms of their pKa values. Vancomycin has a pKa value of 8.78 while ceftriaxone sodium has a pKa value of 3.96.

CVMC Technology Venus Remedies Ltd. has come up with CVMC Technology to overcome this chemical incompatibility. CVMC Technology implies Chemical Vector Mediated Compatibility Technology where a vector or chemical agent prevents any interaction between the two drug components. The Chemical Vector contains the following components: A compatibility/stabilizing agent from the group of L-histidine, L-arginine and Llysine in the ratio of 10-45 % of total weight of the mixture. L-histidine (which is an amphoteric amino acid) acts as a buffering agent. The pKa of histidine is close to neutral pH; it can therefore both accept and donate protons. EDTA in the range of 10 to 100 mg/ml. EDTA acts as chelating agent for the ions present in the solution and thus prevents further precipitation. A pH neutralizing agent that maintains the solution pH in the range of 7 to 9. Since the pH difference between the two drugs is wide, the pH of the solution is maintained between 7 to 9 by using a pH neutralizing agent. Patent Venus Remedies has obtained the patent for this technology in US, South Africa as well as New Zealand. The US Patent was granted in August,2011 and is valid upto 2027 (US7960337B2). The patent suggests parenteral (preferably IV) route of administration for both the antibiotics(in the form of vancomycin hydrochloride & ceftriaxone sodium respectively). Suitable solvent vehicle is aqueous based with no deleterious reactions,preferably 0.9% Sodium Chloride, 5% Dextrose injection.